Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no...
Principais autores: | Hannes Lengauer, Damjan Makuc, Damjan Šterk, Franc Perdih, Arthur Pichler, Tina Trdan Lušin, Janez Plavec, Zdenko Časar |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
MDPI AG
2020-04-01
|
coleção: | Pharmaceutics |
Assuntos: | |
Acesso em linha: | https://www.mdpi.com/1999-4923/12/4/342 |
Registros relacionados
-
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
por: Giacomo Stroffolini, et al.
Publicado em: (2024-02-01) -
Antiviral Efficacy and Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B
por: Tuvshinbayar Narangerel, et al.
Publicado em: (2020-12-01) -
Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
por: Ping‐Feng Wu, et al.
Publicado em: (2024-12-01) -
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Pei-Yuan Su, et al.
Publicado em: (2021-11-01) -
Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
por: Kensuke Abe, et al.
Publicado em: (2024-02-01)